Navigation Links
Blood levels of immune protein predict risk in Hodgkin disease
Date:12/10/2012

Blood levels of an immunity-related protein, galectin-1, in patients with newly diagnosed Hodgkin lymphoma reflected the extent of their cancer and correlated with other predictors of outcome, scientists reported at the American Society of Hematology annual meeting.

In a study of 315 patients from a German database, researchers from Dana-Farber Cancer Institute found that serum galectin-1 levels "are significantly associated with tumor burden and additional adverse clinical characteristics in newly diagnosed Hodgkin lymphoma (HL) patients."

The measurements were made possible by a new laboratory test called a "sandwich ELISA" devised by the Dana-Farber team, led by Margaret Shipp, MD, director of the lymphoma program at Dana-Farber. Galectin-1 is a protein which, when overexpressed by Hodgkin lymphoma cells, allows them to evade the body's immune response that normally would detect the cancer and attack it with cell-killing lymphocytes. The Shipp group developed antibodies that recognize the galectin-1 protein and were used in developing the sandwich ELISA assay.

Since the protein is secreted into the bloodstream, the investigators hypothesized that measuring relative levels of galectin-1 in newly diagnosed, untreated Hodgkin patients could help to assess likely outcomes in those patients. Such predictions, in turn, could help physicians decide how aggressively to treat the lymphoma, Shipp explained. With further development, she added, the assay could become "an objective test that might help make decisions on which way to treat patients."

The Dana-Farber scientists collaborated with researchers of the German Hodgkin Study Group (GHSG) at the University Hospital of Cologne. Shipp said that the GHSG has "probably the largest, most comprehensive data on clinical trials of patient with well-defined Hodgkin lymphoma." The 315 patients whose blood levels of galactin-1 were tested in the study had been enrolled in three different clinical trials one for early-stage disease, a second for early-stage disease with additional less-favorable risk factors, and the third for patients with bulky localized or advanced-stage disease.

Using the sandwich ELISA assay, the Dana-Farber investigators found that blood galectin-1 levels in Hodgkin lymphoma patients were significantly higher than in normal control patients. They also found that relative galectin-1 levels were correlated with the risk factors that had been used to assign the 315 patients to the three different clinical trials. Direct comparisons of the galectin-1 levels with patient outcomes are awaiting the completion of one of the clinical trials, the researchers noted.

Beyond the potential for a clinical test, galectin-1 holds promise as a therapeutic target, said Shipp, whose group has made a "neutralizing" antibody to block the protein. She said the antibody, which is produced in mice, would need to be "humanized," or genetically modified to be compatible with human patients, and then undergo rigorous testing for safety and efficacy. This is under discussion with potential industrial partners, said Shipp.


'/>"/>

Contact: Teresa Herbert
teresa_herbert@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute
Source:Eurekalert

Related medicine news :

1. Infection Might Raise Blood Clot Risk for Older Adults: Study
2. Normalizing tumor blood vessels improves delivery of only the smallest nanomedicines
3. Common Blood Pressure Drug Safe for Heart Failure: Study
4. Certain Birth Control Pills May Carry Higher Blood Clot Risk: FDA
5. High Blood Pressure May Be Especially Lethal for Blacks
6. Changes in gene expression may help explain high blood pressure in pregnancy
7. Researchers Develop Blood Test for Depression
8. Naturopathic care can improve blood sugar, mood in diabetes
9. Diabetes Groups Issue New Guidelines on Blood Sugar
10. Exercise May Help Patients With High Blood Pressure Live Longer
11. Additional blood pressure screening may reduce incidence of CVD events and death by up to 3 percent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Clearwater, FL (PRWEB) , ... March 27, 2017 ... ... accepts new patients for clear braces. People who want straight teeth without the ... Invisalign® in Clearwater, FL, without acquiring a referral. A custom-designed series ...
(Date:3/27/2017)... VA (PRWEB) , ... March 27, 2017 , ... ... 3.0 was transitioned to the OSEHRA popHealth Community in 2014. It ... Work Group and the Developer Open Source Project Group. OSEHRA Organizational Member Zato ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... CE Certificate of Conformity for the Smart System® 20/20. CE Certification builds upon ... industry standards and specifications such as ANSI, ISO and proven test methods used ...
(Date:3/27/2017)... ... 27, 2017 , ... Advantexe Learning Solutions , a ... a new research study, The Business Readiness Report. The report explores the correlation ... the actual success of achieving individual and company goals. , There are ...
(Date:3/27/2017)... ... March 27, 2017 , ... According to the ... including all stages, is more than 95%. Once the cancer spreads to other organs, ... 30%. To find out how to avoid this latter group, tune in to ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Research and Markets has announced the addition of ... their offering. ... The Cell Therapy Manufacturing Market, 2017-2027 report provides an ... manufacturing and focuses both on contract manufacturers and cell therapy ... emerge as viable alternatives to conventional treatment options. ...
(Date:3/24/2017)... PUNE, India , March 24, 2017 According ... Market: Global Opportunity Analysis and Industry Forecast, 2014-2022," the spine bone stimulators market ... million by 2022, growing at a CAGR of 3.6% during the forecast period. ... ... Allied Market Research Logo ...
(Date:3/24/2017)... Calif. , March 24, 2017 /PRNewswire/ ... epigenetics company, and Hamilton Robotics, Inc., who ... announced an ongoing collaboration that teams Zymo ... and RNA and DNA extraction products with ... already created optimized methods for microbiomics and ...
Breaking Medicine Technology: